#United States #New York #Class Action #Gross Law Firm #Nektar Therapeutics

Nektar Therapeutics Shareholder Alert: Class Action Lawsuit

The Gross Law Firm has released an important notice urging shareholders of Nektar Therapeutics (NASDAQ: NKTR) to take immediate action regarding a class action lawsuit. This alert is particularly targeted at individuals who purchased shares of NKTR between February 26, 2025, and December 15, 2025. The deadline for shareholders to register as lead plaintiffs in this case is set for May 5, 2026, and it’s crucial to act promptly to secure your rights.

Key Details for Shareholders

From the allegations raised in the class action suit, it has come to light that during the specified class period, Nektar Therapeutics reportedly issued materially false or misleading information, or omitted critical facts that investors should have been made aware of. Specifically, the complaint points to several serious allegations, including that:

• - Enrollment in the REZOLVE-AA trial did not adhere to necessary protocols as required by applicable standards.
• - This non-compliance is likely to have adversely impacted the results of the REZOLVE-AA trial.
• - The overall integrity and projected outcomes of the trial, as reported by the company, were thus overstated.
• - As a result, the public statements by the defendants were deemed materially false and misleading throughout the class period.

Shareholders who feel they have been misled or suffered losses are encouraged to register with the Gross Law Firm using the links provided in their notice. It’s important to highlight that registering as a lead plaintiff is not mandatory to qualify for potential recovery in this class action.

The Importance of Timely Action

The Gross Law Firm has experienced success in similar class action lawsuits and advocates for the rights of investors who have encountered deceitful practices within the business sphere. Participating in the class action suit at this stage allows shareholders to join efforts for justice and recuperation of their losses. Once you register, the firm will enroll you in a portfolio monitoring software, ensuring that you receive ongoing updates regarding the lawsuit's progress, giving you peace of mind throughout the entire process.

Next Steps for Interested Shareholders

1. Register Your Information: Interested shareholders need to act fast and register using the sign-up form provided on the Gross Law Firm’s website. The deadline is set for May 5, 2026.
2. Stay Informed: Upon registration, shareholders will receive notifications about their case status, providing a comprehensive understanding of proceedings as they unfold.
3. No Obligation to Participate: It should be noted that there are no costs or obligations associated with joining the class action lawsuit, making it a risk-free opportunity to seek justice.

Why Choose The Gross Law Firm?

The Gross Law Firm is regarded as a nationally recognized class action law firm dedicated to safeguarding shareholders' rights in cases of fraudulent behaviors and management malpractice. Their mission emphasizes a commitment to corporate accountability, aiming to rectify the adversities faced by investors when companies issue misleading information leading to unjustified market consequences.

In conclusion, if you are a shareholder of Nektar Therapeutics who acquired shares within the specified timeline, now is the time to act. The Gross Law Firm stands ready to assist you in this class action litigation, aiming to protect your rights and recover your losses effectively.

For more information, contact the Gross Law Firm directly:
Phone: (646) 453-8903
Email: [email protected]
Address: 15 West 38th Street, 12th Floor, New York, NY 10018.